Microglial Pipeline: What makes us different?

• OWL-1023-AI (late preclinical): A best-in-class monoclonal antibody engineered to supercharge microglia, enhancing their ability to eat brain cell debris.

• OWL-4130-AI (late preclinical): A best-in-class fusion protein engineered to supercharge microglia, enhancing their ability to clear inflammation.

• OWL-1410-AI (early preclinical): A best-in-class small molecule to supercharge microglia, enhancing  protection of their mitochondrial “powerhouses”.

Through a partnership with Gryphon Bio, we reverse-translate blood biomarkers from clinical studies to improve the odds of successful preclinical studies, as well as future clinical trials, with our microglial drugs.

We develop and apply novel generative AI tools to engineer large and small molecule drugs that supercharge microglia-with predicted improvements in efficacy and safety. We verify our predictions with high throughput experiments for microglial clearance,  inflammation, and mitochondrial function.

Drug development for TBI accelerates drug development for AD.

• Unlike AD, TBI clinical trials have a clearly defined time of disease onset such that all patients are “in-phase”.

• For this and other reasons, TBI preclinical studies and clinical trials are faster and more cost-effective than those for AD.

• Blood biomarkers provide clearly defined endpoints for both TBI and AD-with strong overlap.

• TBI, like age and genetics, is a risk factor for AD.